DDAH1 and melanoma: Recently, high expression of DDAH1 has been linked to poor clinical outcomes in certain cancers, such as breast cancer, melanoma, and hepatocellular carcinoma.[12, 13, 14] However, the role of DDAH1 in cisplatin resistance in patients with LANPC remains largely unknown.